The NCI Cancer Prevention Steering Committee (CPSC) was established in 2017. The CPSC addresses the design, prioritization and evaluation of concepts for clinical trials to prevent cancer. The CPSC will evaluate innovative cancer prevention, screening and surveillance concepts (i.e., phase 2 and phase 3 randomized trials) across a broad range of cancer and precancerous conditions in diverse patient populations that are seen within the NCI Community Oncology Research Program (NCORP). The committee will also evaluate proposals for the Biomarker, Imaging, and Quality of Life Studies Funding Program (BIQSFP) associated with cancer prevention clinical trial concepts
The core committee membership includes representatives from NCORP Research Bases, prevention experts, R01 investigators, community oncologists, biostatisticians, patient advocates and NCI Staff. View the CPSC member roster as of November 7, 2025.
The CPSC may periodically hold clinical trials planning meetings (CTPMs) to identify critical questions and prioritize key strategies related to cancer prevention, screening and surveillance.
Contact
For more information, contact NCI CCCT Program Director, Mehrdad Mohseni, M.D. at mehrdad.mohseni@nih.gov.